Daily Stock List
Network CN, Inc. (NWCN)
SmallCap Fortunes reported earlier on Network CN, Inc. (NWCN), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Network CN, Inc.'s focus is on becoming a nationwide leader in providing out-of-home advertising in the People's Republic of China (PRC), mainly serving the needs of branded corporate customers. They look to acquire rights to install and operate roadside advertising panels and mega-size advertising panels in the major cities in the PRC. Their focus is primarily on their growing media platforms in Beijing, Shanghai and other major cities in the country. Network CN is based in Causeway Bay, Hong Kong.
Since August 1, 2006, Network CN has been operating a growing advertising network of roadside LED digital video panels, mega-size LED (Light Emitting Diode) digital video billboards and light boxes in major Chinese cities. In almost all cases, the Company is responsible for installing advertising panels (in some cases, advertising panels might have already been installed) and they are responsible for operating and maintaining the panels. Once the advertising panels are put into operation, Network CN sells advertising airtime to their customers directly.
Network CN is one of China's fastest growing companies in the out-of–home media sector. Their one-stop suite of services ranges from media planning to advertising operations in the media sector. Starting from January of 2007, Network CN has continuously acquired different advertising companies.
Last month, Network CN announced that their wholly owned subsidiary, Yi Gao Shanghai Advertising, entered into an Agreement to co-operate with "Shanghai New Athletes Travel Limited" to operate the advertising area of the No. 2 Building in Shanghai New Athletes' City, Putuo District, Shanghai. Under the signed Agreement, Shanghai New Athletes Travel is the owner of the No. 2 Building in the City, and Network CN will be responsible for the media planning, and to operate the advertising media of the building. The Agreement is signed with a one-year term from November 17, 2012 to November 16, 2013. The City is located in Putuo District, Shanghai with a total area of 16,700 square meters.
Network CN, Inc. (NWCN), closed Wednesday's trading session at $0.12, up 7.14%, on 2,100 volume with 3 trades. The average volume for the last 60 days is 6,536 and the stock's 52-week low/high is $0.012/$0.55.
Minco Gold Corp. (MGH)
SmarTrend Newsletters and SmallCap Fortunes reported earlier on Minco Gold Corp. (MGH), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Based in Vancouver, British Columbia, Minco Gold Corp. is a mining company that engages in the direct acquisition and development of high-grade, advanced stage gold properties. They own an exploration property portfolio covering more than 1,000 square kilometers of mineral rights in China. Minco Gold currently owns 16 gold properties covering this area of mineral rights in China. Minco Gold's short-term goals are to bring primary projects to feasibility, and look for new acquisitions. Their long-term goal is to become a significant gold producer and exploration partner in China.
The Company has multi-property drilling and field evaluation planned or underway. The Company has strong relationships with premier Chinese mining organizations. Minco Gold is well funded; they have experienced management teams in Canada and China. In addition, the Company has strong operating expertise and a large geological database. The Company's Projects include the Changkeng Gold Deposit, located approximately 45 km southwest of Guangzhou, China; the Yangshan Gold Belt - Longnan Project, located in Gansu Province, within the southwest Qinling gold field, in China, and the Gold Bull Mountain (Jinniushan) property located in Yuanling County, Western Hunan Province, in China.
Their subsidiary is Minco Mining (China) Co., Ltd. This subsidiary was incorporated in China to manage the Company's projects in China, enhancing the Company's management team in China, and expanding upon certain mining activities (such as staking) in China.
In April 2012, Minco Gold announced the start of the planned exploration program for their 100 percent owned Longnan Project located in Gansu Province, China. The Company has successfully maintained twelve exploration permits in the South of Gansu province, collectively referred to as the Longnan project. They are intensifying exploration activity because of progress made through the 2010 and 2011 exploration programs. These programs defined multiple drill targets at Shajinba and Baimashi in the Yejiaba area.
Minco Gold's 2012 exploration program is primarily focusing on the Yejiaba area of the Longnan Project. The exploration program includes surface trenching and sampling, approximately 3,000 meters of diamond drilling in eight holes, and 3,000 meters of underground tunneling.
In November, Minco Gold announced that Mr. Peter Voulgaris was appointed as Vice President of Corporate Development and Mrs. Ellen Wei, the Company's interim CFO, was promoted to Chief Financial Officer, of the Minco Group of Companies. They also announced the appointment of Mr. Samson Siu as Controller of the Minco Group of Companies.
Minco Gold Corp. (MGH), closed Wednesday's trading session at $0.41, up 5.13%, on 113,713 volume with 96 trades. The average volume for the last 60 days is 51,074 and the stock's 52-week low/high is $0.335/$0.98.
Vu1 Corp. (VUOC)
FeedBlitz, M2 Communications, Stock Guru, Stock Traders Chat, Stock Rich, CoolPennyStocks, BullRally, and HotOTC reported previously on Vu1 Corp. (VUOC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Bulletin Board, Vu1 Corp. focuses on designing, developing and selling a line of mercury-free, energy efficient lighting products based on their proprietary light-emitting technology (Electron Stimulated Luminescence™ (ESL) technology). In late 2007, the Company started investing in a high-volume manufacturing capability. Consequently, a unique manufacturing process was developed to produce an affordably priced Vu1 branded light bulb. The Company was formerly known as Telegen Corp. They changed their name to Vu1 Corp. in May of 2008. Founded in 1990, Vu1 is based in New York, New York.
Electron Stimulated Luminescence™ (ESL) Lighting Technology uses accelerated electrons to stimulate phosphor to create light. This makes the surface of the bulb "glow". ESL technology creates the same light quality as an incandescent. However, it is up to 70 percent more energy efficient. It lasts up to five times longer than incandescent and contributes to the reduction of greenhouse gas emissions. There is no use of the neurotoxin Mercury (Hg) in the lighting process.
The ESL light is considered the closest in light quality to incandescents. It goes a step further by approaching a nearly ideal standard – known as Lambertian light – which produces a full-spectrum glow that is most intense at the work surface. With the Company's ESL lighting, all colors are reproduced, resulting in a "natural," pleasing glow.
In October 2010, the Company received UL certification for their R30 light bulb. The R30 is a clean, energy efficient alternative to a standard incandescent 65-watt flood light bulb for recessed ceiling cans. Vu1 has plans in place to introduce the classic A-type lamp for U.S. and European consumers, the R40 for the U.S. commercial market, and the R25 in Europe. The Vu1® reflector bulb gives uniform flood illumination and a light quality that is virtually indistinguishable from the incandescent lamp it replaces.
Vu1 Corp. (VUOC), closed Wednesday's trading session at $0.61, down 6.15%, on 3,843 volume with 5 trades. The average volume for the last 60 days is 3,677 and the stock's 52-week low/high is $0.55/$6.25.
PuraMed BiosScience, Inc. (PMBS)
MoneyTV reported recently on PuraMed BiosScience, Inc. (PMBS), SmallCapVoice, OTC Stock Review, Investor Voice did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTCBB, PuraMed BiosScience, Inc. engages in the research, development, and marketing of non-prescription medicinal and healthcare products. The Company's lead product is LipiGesic® M, a sublingual acute treatment for the relief of migraine headaches. In addition to LipiGesic® M, PuraMed BiosScience also has plans to launch LipiGesic® H for tension-type headaches, and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. PuraMed BiosScience has their headquarters in Schofield, Wisconsin.
The Company has recently completed all product development and design packaging for their initial three products. A second, longer term, opportunity for the Company is to establish a leadership position in the highly fragmented Over-the-Counter (OTC) natural and alternative health remedy market by introducing a "new kind of product line." PuraMed's product line will consist of 'alternative' remedies for common ailments, marketed to the masses.
Currently, PuraMed BioScience is undergoing substantial activities to gain extensive retail distribution via mainstream drug store chains, mass merchandisers, and food chains. The Company has gained a retail presence in two of the top national chain drug stores, Walgreens and CVS. The number of stores now stocking their LipiGesic® M migraine product is almost 15,000 stores. In addition, PuraMed is in negotiations with a number of additional large retailers to stock their LipiGesic® M, migraine product.
Furthermore, the Company's intention is to continue to develop and grow their Intellectual Property (IP) portfolio. PuraMed's scientific team has gained significant evidence from their initial research and management. The Company expects that this will assist them in the development of a new generation of botanically derived anti-inflammatory and pain management products with broad applications.
Last month, PuraMed BioScience announced that their homeopathic migraine formulation, LipiGesic® M, received recognition as an excellent first-line therapy in the treatment of acute migraine. The declaration was made in the online article "Advances in Drug Development for Acute Migraine," [page 14] scheduled for publication in an upcoming printed issue of Drugs, a medical journal evaluating drugs and drug therapies, and read by more than 500,000 healthcare providers.
Authors Ryan J. Cady, Candace L. Shade, and Roger K. Cady, MD, reviewed 11 drugs considered advancements in acute migraine treatment. LipiGesic® M was the only product described as "an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."
PuraMed BiosScience, Inc. (PMBS), closed Wednesday's trading session at $0.05, up 44.93%, on 1,150,000 volume with 33 trades. The average volume for the last 60 days is 76,632 and the stock's 52-week low/high is $0.0112/$0.50.
Abington Resources Ltd. (ABL.V)
Today we are highlighting Abington Resources Ltd. (ABL.V), here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, Abington Resources Ltd. engages in the acquisition, exploration and development of oil and gas and mineral properties, particularly precious metals. The Company's Directors have more than 50 years combined experience in public companies, financing and mining. Incorporated in 1999, Abington Resources has their headquarters in Vancouver, British Columbia. The Company formerly went by the name Abington Ventures, Inc. They changed their name to Abington Resources Ltd. in October of 2009.
The Company's portfolio of properties consists of the Juniper Property and the Kingsford and Weyburn Oil Properties. Concerning the Juniper Property, in early January of this year, Abington exercised a Letter of Intent (LOI) to enter into a lease agreement on 110 unpatented lode claims in Pershing County, Nevada, south of Winnemucca. The claim's exploration history includes work done by companies such as Newmont, Morrison-Knudsen Gold (MK Gold) and others. There is evidence of historic placer and lode exploration being done in this region. Abington is now undergoing their initial due diligence on the Juniper Property.
Terms of the ten-year lease for the Juniper Property include advance minimum Royalty Payments: to establish rights for the first year -$25,000US (paid); First Anniversary - $50,000US; Second Anniversary - $50,000US; Third Anniversary - $75,000US; Fourth Anniversary - $100,000US increasing by $25,000 each subsequent Anniversary.
Concerning Annual Work Commitments: there is no commitment for the Initial Year or First Anniversary year, Second Anniversary year - $100,000US; Third Anniversary Year $150,000US, Fourth Anniversary Year $200,000US increasing by $50,000US each subsequent Anniversary year. The Juniper property will carry a 3 percent Net Smelter Return (NSR) with an option to purchase one percentage point at $1,000,000 per one-half percentage point.
Pertaining to the Kingsford and Weyburn Oil Properties, these are Joint venture oil projects in Saskatchewan. Both of these are currently producing. These properties afford positive cash flow to Abington Resources. They have the potential for additional offset wells.
Concerning the Weyburn Property, in 2002, Abington agreed to purchase an interest in two horizontal oil and gas producing wells in southeastern Saskatchewan. Concerning the Kingsford Property, in 2002, Abington agreed to purchase an interest in one oil producing well located in Kingsford, Saskatchewan.
Abington Resources Ltd. (ABL.V), closed Wednesday's trading session at $0.115, down 11.54%, on 9,165 volume. The stock's 52-week low/high is $0.11/$0.95.
Ergoresearch Ltd. (ERG.V)
We are highlighting Ergoresearch Ltd. (ERG.V), here at the QualityStocks Daily Newsletter.
Ergoresearch Ltd. has developed Quebec's leading network of orthotics clinics, with more than 60 corporate and satellite centers under the Clinique du pied Équilibre and Orthoconcept banners. The Company works in the field of healthcare and they have been developing innovative products and solutions that affect pain management and are economically efficient. Ergoresearch products are biomechanical devices (class 1), non-invasive and non-toxic.
The Company, based in Laval, Quebec, is a leading manufacturer of "intelligent" foot orthotics and specialty orthotics. They focus on creating durable medical equipment and software for the orthopedics market. Ergoresearch has developed and commercialized Expert-Fit™, the first robotized custom-fit orthotics manufacturing software program, and launched the first Living Lab in Canada. They have also developed a new generation of world-patented orthotic devices called the OdrA. This device transforms the treatment of pain associated with knee osteoarthritis.
Ergoresearch designs and produces a spectrum of ortheses, braces and orthotics. They were the first to develop and market podo-barometric sensor pads (pressure point pads) on a large scale. In May 2011, Ergoresearch opened their first Living Lab in Canada specializing in knee osteoarthritis, a centre for excellence located in Laval, Quebec.
In November, Ergoresearch announced an increase in sales and profitability for the first quarter of the 2013 fiscal year. Sales increased by 18.7 percent to $2,167,916, compared to $1,826,393 for the same quarter a year ago. Earnings before income taxes increased by 21.1 percent to $312,224 compared to $257,734 the year prior.
The Company had a 22 percent increase in operating income. EBITDA increased by 16.9 percent to reach $426,625 or 19.7 percent of sales. Cash flows generated from operating activities rose by 81.7 percent to $256,504. Cash on hand and temporary investments amounted to $2,597,321 as of September 30 2012.
In addition, in November, Company Management at Ergoresearch announced that they acquired all issued and outstanding shares for Laboratoire Podotech, a firm headquartered in Laval. Podotech is a Quebec firm offering specialized assessment and manufacturing services for custom-fit foot orthotics and custom made shoe and "comfort" shoe sales in the Laval and Lower Laurentian regions. Podotech shares were acquired by way of an Ergoresearch subsidiary, Orthoconcept (2008) inc., 51 percent of which is owned by Ergorecherche, Inc.
Ergoresearch Ltd. (ERG.V), closed Wednesday's trading session at $0.70, up 2.94%, on 2,500 volume. The stock's 52-week low/high is $0.11/$0.68.
ARCA biopharma, Inc. (ABIO)
SmarTrend Newsletters, AllPennyStocks, and The Street reported earlier on ARCA biopharma, Inc. (ABIO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
ARCA biopharma, Inc. is a biopharmaceutical company that lists on the NASDAQ Capital Market. The Company is developing genetically targeted therapies for atrial fibrillation and other cardiovascular diseases. The Company's lead product candidate is Gencaro™ (bucindolol hydrochloride). ARCA holds exclusive, global rights to Gencaro. The Company has been granted patents in the U.S. and Europe for methods of treating various cardiovascular disorders with Gencaro based on these genetic variations. ARCA biopharma has their corporate headquarters in Broomfield, Colorado.
Gencaro™ (bucindolol hydrochloride) is an investigational, pharmacologically unique beta-blocker and mild vasodilator undergoing development for atrial fibrillation (AF). The Company has identified common genetic variations that it believes predict individual patient response to Gencaro. This gives it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA biopharma has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro.
The Company is planning to initiate a Phase 3 clinical study of Gencaro in AF patients with heart failure and reduced left ventricular ejection fraction (HFREF), known as GENETIC-AF. ARCA believes AF is an attractive indication for Gencaro because data from BEST (the previously conducted Phase 3 HF trial involving Gencaro in 2,708 HF patients) suggest Gencaro may have a potentially significant effect in reducing and/or preventing AF.
Today, ARCA biopharma announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published in the European Journal of Heart Failure (www.escardio.org/journals/european-journal-heart-failure), a publication of the Heart Failure Association of the European Society of Cardiology.
This paper discusses post-hoc analyses of data from the Phase 3 clinical study of Gencaro in heart failure, called the Beta-Blocker Evaluation of Survival Trial (BEST), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs. The data demonstrates that patients with established atrial fibrillation (AF) in BEST who received Gencaro had improvements in heart failure clinical endpoints.
ARCA biopharma was granted patents in the United States, Europe, and other jurisdictions for methods of identifying and treating patients with the beta-1 389 arginine homozygous genotype. They plan to conduct the aforementioned Phase 3 clinical trial to evaluate Gencaro as a potential treatment for the prevention of AF in patients with this genotype, subject to receiving the necessary funding.
ARCA biopharma, Inc. (ABIO), closed Wednesday's trading session at $0.45, up 24.31%, on 2,990,653 volume with 3,355 trades. The average volume for the last 60 days is 142,788 and the stock's 52-week low/high is $0.23/$1.42.
Highpower International, Inc. (HPJ)
Green Chip Review and Greenbackers reported previously on Highpower International, Inc. (HPJ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Highpower International, Inc. is a clean energy group whose dedication is to the Research & Development (R&D), production and sales of rechargeable Ni-MH Batteries, Lithium batteries, and battery systems. Additionally, they recycle waste batteries and reprocess raw materials for batteries. The Company employs an extensive network of sales staff in the People's Republic of China (PRC) and Hong Kong that targets key customers by arranging in-person sales presentations and providing post-sale services.
Founded in 2001, the Company formerly went by the name Hong Kong Highpower Technology, Inc. They changed their corporate name to Highpower International, Inc. in October of 2010. Incorporated in the state of Delaware on January 3, 2006, Highpower International is headquartered in Shenzhen, the PRC. Their distribution network has covered North America, Europe, and China & Hong Kong, Southeast Asia, Korea and several other countries and regions.
On November 2, 2007, Highpower International closed a share exchange transaction, and with this, they became the 100 percent parent of HKHTC and their wholly owned subsidiary, SZ Highpower, and assumed the operations of HKHTC and their subsidiary.
Through SZ Highpower, Highpower International manufactures Nickel Metal Hydride (Ni-MH) batteries for consumer and industrial applications. In 2008, they began manufacturing two lines of Lithium-Ion (Li-ion) and Lithium polymer rechargeable batteries via SZ Springpower for higher-end, high-performance applications. These include laptops, digital cameras and wireless communication products.
In 2010, Highpower International started a new materials business in which the Company buys and resells certain raw materials related to their battery manufacturing operations. This new materials business generates revenue and income and helps Highpower understand their raw material supply chain, control their raw material costs, and ensure that they have a steady supply of raw materials for their battery manufacturing operations to reduce the Company's reliance on external suppliers.
Last month, Highpower International announced financial results for the third quarter ended September 30, 2012. Highlights include the Company growing net sales by 13.4 percent year-over-year and 8.5 percent sequentially for the third quarter of 2012 to $31.9 million. They set record sales levels in both major battery segments. Lithium battery net sales were up 87.7 percent over the third quarter of 2011 and 22.4 percent sequentially. Ni-MH battery net sales were up 9.1 percent over the third quarter of 2011 and 0.9 percent sequentially.
They experienced strong gross margin expansion to 23.9 percent in the third quarter of 2012 from 13.8 percent in the third quarter of 2011. They also had continued profitability with EPS attributable to Highpower International of $0.05 for the third quarter of 2012.
Highpower International, Inc. (HPJ), closed Wednesday's trading session at $1.00, up 7.53%, on 16,651 volume with 24 trades. The average volume for the last 60 days is 9,874 and the stock's 52-week low/high is $0.74/$1.55.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.04, up 33.33%, on 89,224 volume with 27 trades. The stock’s average daily volume over the past 60 days is 44,132, and its 52-week low/high is $0.0069/$0.07.
Viscount Systems, Inc. announced the appointment of a new COO today, with access control and security industry veteran, and former Honeywell Access Systems ($100M+ division of Honeywell International) President, Dennis Raefield stepping into the role. This is a step up from the Board for Raefield to a direct assistance role in helping VSYS grow to the next level and he will be working closely with the company's CEO, Stephen Pineau, to develop the architecture needed to handle the rapid growth from the new Freedom access control platform. Freedom is the first and only system that allows entry devices and other building automation systems to be connected to standard building IT networks without requiring expensive control panels that are programmed from a PC.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Viscount Announces Completion of $500,000 Private Placement
Viscount Systems Wins Contract with Phoenix Sky Harbor Sky Train
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.43, up 22.86%, on 23,015 volume with 9 trades. The stock’s average daily volume over the past 60 days is 9,721, and its 52-week low/high is $0.18/$1.87.
GlobalWise Investments, Inc. offered markets an update today on the successful clinic expansion for Sycle.net (http://web.sycle.net/), which has rapidly risen to a standpoint of industry leadership in hearing care practice management since inception in 2002, as well as led the extremely successful product release and ongoing annuity stream billing of the eDocs cloud based software in 215 audiology clinics across the country. CEO of GlobalWise, William "BJ" Santiago, extolled the merits of the eDocs platform, whose ease and simplicity of integrating the cloud-based Intellivue™ software into existing ERP software solutions sets a new standard in open API development.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Channel Partner Sycle.net Continues to Deliver New Clients
GlobalWise Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance
GlobalWise Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.03, up 15.38%, on 580 volume with 1 trade. The stock’s average daily volume over the past 60 days is 391,949, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Achieves Current Information Status on OTC Markets
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
Bergamo Acquisition Updates Financials
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.75, up 0.67%, on 2,100 volume with 3 trades. The stock’s average daily volume over the past 60 days is 1,497, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
Some of this year’s biggest profits are being generated by cloud-enabled software service providers like GlobalWise Investments. Cloud computing is convenient, cost effective, secure, and environmentally friendly. With the amount of data (both structured and unstructured) nearly doubling each year and online file sharing becoming a necessity, cloud computing is being adopted by businesses at an exponential rate.
GlobalWise’s management team boasts a collective 150+ years of ECM industry experience. Leveraging the expertise of its executives and key department heads, GlobalWise has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry.
There are a number of big names in the industry space including Microsoft, Oracle, IBM, Workday, and Open Text. This indicates the opportunity and growth potential of this industry, yet GlobalWise’s target market is uniquely different. By targeting small and medium size businesses, the company is able to aggressively pursue more opportunities.
GlobalWise has a highly scalable business model and its platform is Open Database Compliant (ODBC) for seamless integration into virtually any existing database environment. The company’s products are designed with the look and functionality of Windows and the software is simple to deploy, use, and maintain.
During the last year, GlobalWise has firmly established its position as a mass-market software provider. The company currently has clients in 23 states and Central America and has announced plans to expand its reach to South America, Europe, and Asia. The company has already partnered with well-established companies like Samsung, Dell, and Lexmark and expects to add a number of additional channel partners in the near term.
To learn more about GlobalWise and the growth strategies being employed, visit www.GlobalWiseInvestments.com
As an enthusiast for the latest tech toys, I’ve bought and tried a lot of great and not-so-great products over the years. When a person buys a product that isn’t considered “mainstream” yet, they accept a pretty high level of risk. Quite often it will fall short of promises, come with frustrating bugs that still have to be worked out, or will die prematurely because of cheap materials or poor testing protocols. However, every so often a game-changer enters the market and makes the consumer wonder how they could ever go back to life the way it was.
The Guitammer Company’s ButtKicker systems are literally changing the game (or whatever else you throw at it – movies, music, etc.). Do you remember the first time you had the big screen experience in someone’s living room? What about your reaction to your first home theater surround sound demonstration? If you now have these items in your own home, you know the disappointment when you have to watch a movie on a modest-sized TV with just the built-in stereo speakers.
So what is the ButtKicker exactly? The company calls it a silent subwoofer that turns any home theater into a 4D theater, allowing viewers to truly feel all the action in their living room for the very first time. ButtKicker-brand products use the subwoofer channel to shake your entire couch precisely in sync with the movie, video game, or music that is being played. Having a ButtKicker hooked up changes everything.
When they say the whole couch, they mean the whole couch! There are no empty promises or exaggerations here. I have a very heavy couch with each end functioning as a recliner. The powerful effects produced by the ButtKicker made it all the way down the leg rest on each end. Just like in real life, when an explosion goes off, you can feel it all the way up and down your body.
Although watching movies and listening to my favorite songs with the ButtKicker was awesome, playing an action-packed game like Call of Duty brought the most excitement. It’s a total different experience when you shoot your weapon and actually feel the recoil. When was the last time you were playing a game and your whole body felt the impact after you pulled the trigger? Trust me, it’s a total different experience compared to a controller weakly vibrating in your hands.
I decided on the wireless ButtKicker kit because it had everything I needed in the box and promised to be very easy to setup. Although it only takes 30 minutes to setup your ButtKicker system, you won’t leave the room for hours after you start getting it out of the box. I had a blast watching movies, listening to all kinds of different songs, and playing various video games throughout the night. Even during the quiet parts, my ButtKicker found a way to bring the entertainment to life in ways I’ve never experienced before.
There is a lot more that could be said about the experiences I had when trying different games, music genres, and films (even family videos like Finding Nemo pack a big punch). But, honestly, there is only one way to fully understand what it is like and that is to try it yourself. The Guitammer Company gladly takes all the risk by offering a money-back guarantee, so there’s no reason not to try it out.
Right now the company has a number of great holiday deals on popular systems. The Wireless ButtKicker system I got (which comes with everything you need) is being sold for just $379.99 with free shipping (over 20% off). To see what else is on sale for the holidays, visit: http://dtg.fm/gtmm-holiday-deals.
For more information on ButtKicker products, visit www.ShakeMyCouch.com
Trans-Lux’s digital signage display solutions are used in the financial, sports and entertainment, gaming and leasing markets, both for indoor and outdoor applications. Since its conception more than 80 years ago, the company’s display equipment has been installed at thousands of locations worldwide, including major financial exchanges.
The company’s TL Vision outdoor large screens leverage cutting-edge LED technology to generate high definition for large scale imaging ideal for stadiums, billboards, marquees, casinos, and other outdoor applications.
The TL Vision LED indoor screen system is available for scalability, and can be custom configured to any shape and size. The company’s LED pitches range from 3mm to 127 mm.
Trans-Lux president and CEO J.M. Allain in a recent press release said that the company anticipates new and innovative sales programs that will generate additional business opportunities and enhance the company’s competitive position in the LED market.
For the recently reported third quarter ended September 30, 2012, Tans-Lux swung to profit with earnings of $0.02 million, or a loss of $0.01 per share, compared to a loss of $2.2 million, or a loss of $0.88 per share, reported for the third quarter of last year. Sales for the quarter were $5.9 million, a decrease compared to sales of $7.1 million for the comparable quarter of 2011.
For the nine months ended September 30, 2012, Trans-Lux incurred a loss of $0.7 million, or a loss of $0.06 per share, as compared to a loss of $5.5 million, or a loss of $0.23 per share, for the same nine months of 2011. Revenue for the nine-month period was $18.4 million, up from $17.1 million in the same period of last year.
For more information visit www.trans-lux.com
LoJack yesterday announced it has entered into an agreement with the largest Ford dealership in the world, Galpin Ford, to install the LoJack Stolen Vehicle Recovery System on Galpin’s vehicle fleet. This agreement is the largest of its kind to be established between LoJack Corporation and a single dealer, representing a strategic direction LoJack is taking with topflight dealers such as Galpin Ford.
Galpin Ford has been the world’s largest Ford dealership for 22 consecutive years, and the arrangement between the two entities is a win for both. Vehicle thefts are happening increasingly at dealer lots, and Los Angeles particularly – where Galpin Ford is located – is ranked as one of the worst areas in the United States when it comes to car theft. Galpin Ford will now have the best available protection for its entire fleet of vehicles and can readily pass that protection along to customers who purchase the LoJack System. LoJack, in return, will have the endorsement of one of the nation’s largest and most successful car dealerships and the biggest Ford dealership on earth.
The flagship Stolen Vehicle Recovery System offered by LoJack Corporation will be installed on Galpin Ford’s fleet of vehicles, and LoJack will additionally provide value-added services in dedicated training, installation, and marketing. This will include representatives from LoJack who will be onsite at Galpin Ford to deliver personalized training on the LoJack System to the dealership’s entire sales staff. A team of certified installation representatives will also be on hand to install the LoJack System into Galpin Ford’s vehicle fleet. LoJack will additionally work with Galpin representatives on various initiatives to assist in enhancing the overall Galpin Ford customer experience, including analyzing customer traffic flow to offer insights into what attracts customers’ attention within the dealership. Finally, LoJack will develop customized, co-branded collateral on the LoJack System to enable Galpin to distribute educational marketing materials to customers.
Over the course of more than 25 years, LoJack Corporation has assisted more than 9 million people in protecting their vehicles from theft. Today, the company provides safety, security, and protection for a constantly growing range of valuable assets and people.
For more information, visit www.lojack.com
Today's Top 3
First Penny Picks
First Microcap Report
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report With the Securities and Exchange Commission
- Cardium Therapeutics, Inc. (CXM) Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
- DoMark International, Inc. (DOMK) Subsidiary and Infrared/Solar Apple Accessory Leader, SolaWerks™, Launches New Website
- The Guitammer Company Inc. (GTMM) Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
- GlobalWise Investments, Inc. (GWIV) Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance
- International Stem Cell Corp. (ISCO) Announces Significant Progress Towards Clinical Development
- Loans4Less.com, Inc. (LFLS) Reports Financial Results for the Third Quarter of 2012
- TNI BioTech Inc. (TNIB) Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
- Viaspace, Inc. (VSPC) Board Chairman and CEO Conduct Interview With The Green Baron Report
- VistaGen Therapeutics, Inc. (VSTA) Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™